TuHURA Biosciences Reports Preliminary Responses in IFx-2.0 Study
The company said the first three patients showed major objective tumor responses at six months in an open-label study of IFx-2.0 alongside Keytruda for first-line treatment of metastatic Merkel cell carcinoma.